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Secondary population-based cervical cancer screening 
has not been implemented successfully in resource-
poor settings or developing countries anywhere 
in the world.[1] Reasons for this failure include the 
difficulties of conventional cytology screening and the 
fact that many prerequisites need to be in place and functioning well 
for population-based screening to be implemented; if any one of the 
components fails to deliver, the whole screening programme fails.[2]
Cervical cancer screening in South Africa (SA) is mainly opportunistic, 
and although the National Department of Health has a cervical cancer 
screening policy, it has not been implemented at any level. Opportunistic 
screening tends to over-screen some sub-populations, while many others 
do not take part. In addition, the main target groups are often not well 
represented, including age and sociodemographic groups.[3,4] In SA, the 
communication of results and follow-up of screen-positive women are 
known to be very problematic. Consequently, the incidence of cervical 
cancer remains high and the majority of women who are diagnosed 
present with advanced-stage disease.
To improve screening efforts in SA, new approaches to screening 
need to investigate improvements in uptake, inclusion of the correct 
target population, and successful communication of results.
Primary prevention of cervical cancer is now possible with the 
availability of human papillomavirus (HPV) vaccines targeting 
HPV types 16 and 18, which cause the majority of cervical cancers 
worldwide, as well as in Africa.[5] The target population for primary 
prevention is initially girls between the ages of 9 and 11 years 
attending primary school. The Vaccine and Cervical Cancer Screen 
(VACCS) project was a cervical cancer vaccine implementation study, 
which also provided the opportunity to investigate the outcome 
of cervical cancer screening when linked to the vaccination of 
schoolgirls. Potential advantages of this approach are the linking of 
two relevant, but different, health interventions aimed at cervical 
cancer prevention and the possibility of exploiting the educational 
and logistic opportunities inherent to school-based programmes. In 
addition, this project utilised new molecular screening technology 
that offered the opportunity to use self-sampling in a home setting.
Methods
This was a national study conducted in Gauteng and Western Cape 
provinces, SA, with the approval of the national and provincial 
departments of Basic Education and Health. The study methodology 
differed slightly between the two provinces, and in this report the 
method and results of the Gauteng arm of the study are described.
In Gauteng, ten primary schools were identified in Atteridgeville and 
the South-West District of Tshwane. After obtaining consent from the 
governing body and principal of each school, information events were 
held at the schools during 2011 and 2012. All the girls in grades 4 - 7 
and their female parents or guardians were invited to attend these events.
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During the information event, attending female parents and guardians 
were interviewed and completed questionnaires (Appendix 1, available 
in the online version of this article), after which they attended a session at 
which information on cervical cancer, the vaccine for primary prevention 
and screening for the disease was provided by a medical doctor in 
the form of a 15-minute PowerPoint presentation as well as through 
the distribution of information leaflets in English or Tswana. During 
the vaccination programme, telephonic interviews were conducted, 
repeating the questions that tested knowledge and screening behaviour 
(Appendix 1, available in the online version of this article).
Female parents and guardians attending the information events 
were invited to take part in self-administered HPV screening and 
to take a screen kit for themselves as well as for a friend or family 
member. The screen kit consisted of a tampon with user instructions; 
women were to insert the tampon vaginally and remove it after one 
hour. The used tampon was placed in a container with buffer and, 
together with personal information, returned to the school in a 
sealed envelope. DNA was extracted from the tampon specimens and 
tested using Roche linear array for HPV DNA testing as described 
previously.[6]
Parents and guardians of girls aged 9 years and older in grades 
4 - 7 were invited to provide consent, and all girls were requested to 
provide consent for HPV vaccination. The vaccine was administered 
per protocol by a team of registered nurses during school hours. Both 
bivalent and quadrivalent vaccines donated by the manufacturing 
companies were available to be administered.
The ages and previous screening histories of women who accepted the 
invitation to screen were determined to assess whether an appropriate 
target population for secondary prevention was reached. HPV test 
results were interpreted as positive if DNA of any of the 15 high-risk 
viral types (16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 68, 73, 82) were 
demonstrated, and as invalid if no DNA amplification occurred as 
tested by the internal control. Women testing positive for the two most 
oncogenic HPV types (16 and 18) were reported separately.
Definitions
The invited cohort (IC) was defined as all female learners enrolled in the 
selected schools in grades 4 - 7. The consented cohort (CC) was defined 
as participants with written consent and assent from the learner. Girls 
with consent whose parents or guardians did not attend vaccine events 
were included in the CC. The vaccinated cohort (VC) was defined as all 
girls who received one vaccine dose. Vaccine uptake rates were calculated 
in a number of ways in order to allow comparison with other published 
HPV vaccine reports. The consented uptake rate (CUR) was calculated 
as VC/CC, with the invited uptake rate (IUR) calculated as VC/IC.
Vaccine completion was calculated using the vaccinated cohort as 
denominator. The vaccine completion rate (VCR) was calculated using 
all girls who received all three vaccine doses. Girls who received only 
two vaccine doses within a short period of time were then separated 
from those who received the two vaccines at least 6 months apart, 
and the latter group was considered sufficiently vaccinated based on 
recent data suggesting protective antibody levels against vaccine HPV 
Table 1. Uptake, vaccination and completion rates in schools vaccinated over one and two calendar years
IC CC VC Single dose
Doses 1 
and 2
Doses 2
and 3 Doses 1 and 3 All 3 doses
Doses 1 and 3, 
+/- dose 2
Description
All girls 
in grades 
4 - 7
All girls 
with 
consent 
and assent
Received 
at least 
one dose
Received 
only 1 
vaccine 
dosage
Received 
2 doses, 6 
weeks apart
Received 
2 doses, 
<6 months 
apart
Received 2 
dosages, 6 
months apart
Received 
all 3 doses
Received at 
least 2 doses, 
min. 6 months 
apart
Three vaccine doses administered within one calendar year: eight schools
B1 61 54 54 0 1 0 0 53 53
B2 87 79 79 2 3 0 1 74 75
B3 183 118 119 1 1 3 6 108 114
B4 223 127 127 0 3 4 3 117 120
B6 123 59 59 1 1 3 7 47 54
B7 166 70 70 1 5 1 2 61 63
B8 181 136 136 0 1 4 0 131 131
B9 155 99 95 3 0 3 40 48 88
Subtotal 1 179 742 739 8 15 18 59 639 698
Vaccination rates IUR 62.9% CUR 99.6% IVR 5.5% VCR 86.5% SVR 94.5%
Three vaccine doses administered over two calendar or school years: two schools
B5 225 159 159 1 43 1 11 103 114
B10 250 158 155 0 22 4 1 128 129
Subtotal 475 317 314 1 65 5 12 231 243
Vaccination rates IUR 66.7% CUR 99.1% IVR 22.6% VCR 73.5% SVR 77.4%
Total Gauteng cohort: ten schools
Total 1 654 1 059 1 053 9 80 23 71 870 941
Vaccination rates IUR 64.0% CUR
99.4%
IVR 10.6% VCR 82.6% SVR 89.4%
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types in similar recipients.[7,8] The insufficiently 
vaccinated rate (IVR) was calculated using the 
number of girls who received only one dose, or 
two doses <6 months apart.
Statistical analysis
Questionnaire data were obtained from 
women who participated in the study and 
consisted of basic demographic data as well 
as data on access to and use of healthcare 
facilities. In addition, knowledge about cervi-
cal cancer and prevention of the disease was 
tested before and after the information event. 
Knowledge scores were calculated by awarding 
points for correct answers to a maximum 
score of 5 marks each for symptoms of, 
screening for and vaccination against cervical 
cancer. Changes in knowledge as tested by 
the same questions asked before and after 
the information event were measured and 
compared between groups. A p-value of <0.05 
was regarded as statistically significant.
Women who participated in self-screening 
were compared with a matched control group 
of women who did not participate. Within 
the participants of self-screening, data from 
all women with positive screen results were 
compared with a matched subgroup of those 
who screened negative. Matching of both 
control groups was done using age and the 
school attended by the child. There were no 
significant differences with regard to level of 
education, employment status and access to 
healthcare between the three groups of women.
The study was approved by the Research 
Ethics Review Committee of the Faculty 
of Health Sciences, University of Pretoria 
(219/2009).
Results
Vaccination data
In the ten schools included in the project, the 
IC consisted of 1 654 girls, of whom 1 059 had 
given full consent (CC); 1 053 girls received 
the first vaccine dose (VC). The CUR was 
99.4% and the IUR 64.0%. In the CC group, 
498 parents or guardians provided informed 
parental consent during the information 
events held at the different schools, while 
561 provided written informed consent on 
the basis of the information leaflet that 
learners took home. Five hundred and 
sixty-nine parents or guardians attended 
the information events and questionnaire 
interviews, while 1 085 received only leaflet 
information. Consent for vaccination 
was therefore provided by 561 of 1 085 
parents (51.7%) who received only leaflet 
information, and by 498 of 569 (87.5%) who 
attended the information events (p<0.0001).
In eight of the ten schools, all three doses 
of the vaccination were completed in the 
same calendar year. Vaccine completion rates 
were superior in these schools compared with 
the two schools in which vaccination was 
scheduled over two calendar years. Vaccine 
uptake and VCRs per school as well as the 
effect of scheduling over one and two calendar 
years are shown in Table 1. No serious adverse 
events related to vaccination were reported.
Screening results
The 569 female parents or guardians 
attending the information events at the 
different schools were invited to take self-
screening kits home. A total of 795 screen 
tests were handed out, of which 253 (44.5%) 
were returned and tested for the presence of 
high-risk HPV (hrHPV) DNA. The mean 
age (standard deviation) of the screened 
population (Fig. 1) was 38.3 (10.2) years 
(95% confidence interval 37.0  - 39.6), and 
the median age was 38.5 years.
Of the 253 samples tested, 9 (3.6%) were 
reported as invalid, 169 (66.7%) tested negative 
for hrHPV and 75 (29.6%) were positive for any 
hrHPV. The hrHPV results are shown in Fig. 2. 
Twenty-three samples (9.1%) were positive for 
HPV type 16 and/or 18, and 52 (20.5%) were 
positive for one or more of the remaining 13 
high-risk types. Of the 75 positive specimens, 43 
(57.3%) had a single type and 32 (42.7%) tested 
positive for more than one hrHPV.
Cervical cancer knowledge
Knowledge scores for cervical cancer symptoms, 
screening and vaccines for the total group before 
and after the educational intervention are shown 
in Fig. 3. Initial knowledge of all aspects was 
insufficient, but improved scores were obtained 
in the second questionnaire.
Considering the screened and unscreened 
groups, there was no difference in initial 
knowledge of cervical cancer and its symptoms, 
which was poor in both groups. Around 70% 
in both groups obtained 0 or 1 out of the 
potential 5 marks awarded. Among women 
who participated in self-screening, the level of 
cervical cancer knowledge improved signifi-
cantly after the information event (n=132; 
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Fig. 2. Molecular results of self-collected cervical screening tests.
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p<0.001) (Table 2), while among unscreened 
women the improvement was not statistically 
significant (n=41; p=0.06) (Table 2).
With regard to knowledge of cervical 
cancer prevention, knowledge of screening 
and vaccination improved significantly 
after the information event among screened 
and unscreened groups (data not shown, 
p<0.001).
Screening behaviour
Self-reported previous screening behaviour did 
not differ significantly between women who 
participated in self-screening compared with 
those who did not (p=0.169); 51.2% of women 
who participated in self-screening reported 
no previous screening ever or did not know 
whether they had had screening in the past, 
compared with 48.8% of non-participants.
It is interesting that after participating in the 
project, 45 of 131 screened women (34.3%) 
reported that their last ‘cervical cancer test’ was 
more than 5 years ago. Despite this disparity, 
there was still a significant improvement in 
reported screening behaviour in this group 
between the two questionnaires (p<0.001) 
(Table 3) compared with the control group, 
which did not show significant improvement 
(p=0.036) (Table 3).
Discussion
Vaccine uptake data differ worldwide and 
are influenced by numerous social, religious 
and economic factors. In addition, vaccine 
programme and communication strategies 
have a very large effect on uptake. Uptake 
of HPV vaccines is low in the USA and 
Germany[9,10] and high in Australia,[11] while 
uptake rates in Africa vary.[12-14]
Vaccine uptake, calculated as the proportion 
of girls who received one vaccine dose from 
the total IC, was 64.0% for the total group in 
this study. The project protocol allowed for 
the provision of only sketchy information to 
prospective participants, because another aim 
of the study was to test baseline knowledge. 
Although it can be argued that interested 
and informed parents were more likely to 
attend, the relatively low vaccine uptake 
(51.7%) among parents who did not attend 
the information event compared with those 
who did attend (87.5%) could probably be 
attributed in part to this lack of information.
Moodley et al.[15] reported overall HPV 
vaccine uptake in an implementation study 
in KwaZulu-Natal Province, SA, of 99.7%, 
97.9% and 97.8% for the first, second and 
third vaccination doses, respectively. These 
data represent the uptake and completion 
rates of those who consented, but uptake as 
a proportion of girls available for vaccination 
was not provided. In the current study, similar 
success in vaccination of consented girls of 
99.4%, 98.6% and 82.6% for one, two and 
all three doses, respectively, was achieved. 
In addition to uptake and completion rates, 
the proportion of the VC that received at 
least two vaccine doses at least 6 months 
apart was calculated. To our knowledge it is 
the first time that HPV vaccine data from 
an implementation or demonstration project 
have been presented in this way, and these 
results therefore cannot be compared.
In a school-based programme, it is 
acknowledged that VCRs are largely influ-
enced by the number of follow-up visits to 
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Fig. 3. Improvement in knowledge scores for cervical cancer symptoms, screening and vaccines.
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the school. In an attempt to simulate large-scale rollout of school-
based vaccination, extra follow-up visits to schools where unforeseen 
school activities and absenteeism prevented a large number of girls 
from attending scheduled vaccination were limited to one. In view 
Table 2. Improved knowledge on cervical cancer and its symptoms (upper triangles of table, above the grey tint) among screened and 
unscreened women
Knowledge about cervical screening: scores after information event
Screened women*
 Knowledge about cervical 
screening: scores before 
information event
Score 0 1 2 3 4 5 Total
0 30 6 11 6 13 6 72
1 4 2 2 6 6 2 22
2 2 2 5 8 2 1 20
3 1 0 1 7 3 3 15
4 1 0 0 1 1 0 3
5 0 0 0 0 0 0 0
Total 38 10 19 28 25 12 132
Unscreened women†
 Knowledge about cervical 
screening: scores before 
information event
Score 0 1 2 3 4 5 Total
0 9 2 6 2 0 0 19
1 2 3 3 1 1 0 10
2 0 2 2 2 1 0 7
3 0 0 0 1 3 0 4
4 0 0 0 0 1 0 1
5 0 0 0 0 0 0 0
Total 11 7 11 6 6 0 41
Score 0 = no correct answer; scores 1 - 5: one mark for each correct answer.
*p<0.001.
†p=0.06.
Table 3. Improvement in self-reported screening behaviour (upper triangles of table, above the grey tint) among screened women but 
not among unscreened women
Self-reported screening behaviour after intervention
Screened women*
 Self-reported screening 
behaviour before 
intervention
Score 0 1 2 3 4 5 Total
0 33 4 1 1 2 25 66
1 0 0 0 0 0 0 0
2 0 0 0 1 1 3 5
3 1 0 0 5 1 2 9
4 2 0 0 0 16 13 31
5 0 0 0 1 4 15 20
Total 36 4 1 8 24 58 131
Unscreened women†
 Self-reported screening 
behaviour before 
intervention
Score 0 1 2 3 4 5 Total
0 11 2 0 0 0 5 18
1 0 0 0 0 0 2 2
2 0 0 0 0 0 0 0
3 0 0 0 0 0 2 2
4 0 0 2 2 6 1 11
5 0 0 0 0 1 7 8
Total 11 2 2 2 7 17 41
Scores: 0 = never; 1 = don’t know; 2 = >10 years ago; 3 = 6 - 10 years ago; 4 = 1 - 5 years ago; 5 = <1 year ago.
*p<0.001.
†p=0.036.
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of this limited effort to improve vaccine completion, the attained 
VCR of 82.6% and a sufficiently vaccinated rate (SVR) of 89.4% are 
considered very satisfactory.
Vaccination in a single calendar year was more successful than 
vaccination scheduled over two years, as reflected by better VCRs 
(86.5% v. 73.5%) and SVRs (94.5% v. 77.4%). The difference can 
possibly be attributed to the December holiday break, children 
changing schools and promotion to secondary schools, which 
resulted in fewer girls receiving the important third dose. Although 
not surprising, this is to our knowledge the first confirmation of this 
effect reported from SA. The projected large loss of immune response 
and resulting herd immunity caused by an inefficiently vaccinated 
population is of huge importance for the planning of all vaccine roll-
out programmes using school-based infrastructure.
Screening uptake, calculated as the proportion of women screened 
from those invited, was 44.5% in this study. Furthermore, in this 
study 253 women took up screening, of whom more than half 
reported no previous cervical cancer screening. Molecular screening 
results identified cervical cancer risk in 28.8% and a high risk for 
future disease in 9.1%. Using the school infrastructure as well as 
mobile phone technology, all women received screen results and this 
was confirmed for all screen-positive women.
All five of these parameters compare favourably to the limited 
data available for the existing cytology-based countrywide screening 
programme. According to the World Health Organization, cervical 
cytology coverage of eligible women in SA for the period 2000 - 2006 
was estimated to be 17%.[16] Screening will have the largest effect 
on cancer incidence if coverage is large, the correct high-risk target 
group is reached, and the biggest possible number of screen-positive 
women can get results and receive preventive therapy. HPV screening 
in low-resource settings is feasible, and self-sampling offers the added 
benefits of eliminating a clinic visit, speculum examination and the 
need for a healthcare provider to perform screening.
In addition to screening, education about cervical cancer symptoms 
and screening was successfully linked to the cervical cancer vaccine by 
the provision of information to parents or guardians of girls invited 
to be vaccinated. Knowledge about cervical cancer-related matters 
was lacking in this group of urban mothers, but improved following 
the provision of information. Neither demographics nor baseline 
knowledge predicted screening uptake in this study. Positive screening 
behaviour was associated with an improvement in knowledge about 
cervical cancer. As expected, most screening participants reported an 
improvement in screening behaviour after the tampon test, reflecting 
an understanding of the intention of the test. The finding that some 
women who took part in self-screening were not aware of the fact that 
they were screened could be attributed to a lack of knowledge or the 
structure of the questionnaire.
Conclusion
Implementation of HPV vaccination in a primary school-based 
programme was hugely successful. No serious adverse events were 
reported, and uptake rates of 64.0% of the IC and 99.4% of the CC 
were achieved. Vaccine completion was optimal when all vaccine 
doses were offered within a single calendar year.
Self-screening tests reached the ideal target group, and results 
were successfully reported to all participants. Linking cervical cancer 
screening to the cervical cancer vaccine was possible by providing 
women the opportunity to self-sample. This is a novel approach that 
would require some adaptive strategies, but was feasible and practical 
in the setting of this trial.
Knowledge about cervical cancer, its symptoms and prevention 
is generally poor, and school-based vaccine programmes offer a 
unique opportunity to provide appropriate information. This report 
of the Gauteng part of the VACCS project confirmed a measurable 
improvement in knowledge following health education. In addition, 
it was demonstrated that improved knowledge correlated with the 
uptake of screening.
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Vaccination and Cervical  Cancer Screening Project 
 
 
COMPLETE THIS TOP SECTION BEFORE STARTING THE INTERVIEW 
 
Participant Study number:                     
     
Interviewer number:       
 
Code for school attended by daughter:   
 
Code for Site:                                                  
 
Date of Interview:              dd    mm    yy   
 
Introductory remarks 
Hello, my name is .....................……….…  Thank you for agreeing to this interview.  I am going to ask you a few questions about 
your understanding of cervical cancer.  It will take about 15 minutes. Your name and contact details that I write down here will be 
kept separate from the questionnaire so anything you tell me will be anonymous and be kept confidential.  Thank you. 
 
 
Participant name   ____________________________________ 
 
Participant ID     
 
Participant Contact Numbers              -   
 
     -  
 
 
Daughter’s Name   ___________________________________ 
 
 
Daughter’s  ID/Birth date   
 
 
Instructions to the interviewer 
 Circle the appropriate number/s or fill in the appropriate response. 
 Follow skip patterns carefully.  DO NOT read words in BOLD or CAPS OR ITALICS 
 Use probes where necessary 
 Circle the NOT MENTIONED options after completion of the interview, before signing completion of form  
 
NB: FILL IN STUDY NUMBERS ON NEXT PAGES AND DETACH THIS FRONT PAGE FROM THE QUESTIONNAIRE AND 
STORE SEPARATELY 
Appendix 1
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SECTION-1: Socio-Demographic Characteristics  
READ: “To start I am going to ask you some questions about yourself” 
No. Questions and filters Coding categories Code Instructions  
101 How old are you? 
 
 
Age in years 
 
Missing  
 
 
[___|___] 
 
-66 
 
102 What is the highest level of education you 
have completed?  
 
CIRCLE ONLY ONE  
No formal schooling 
Grade 1/Sub A to Grade 7/Std 5 
Grade 8/Std 6 to Grade 11/Std 9 
Grade 12/Std 10  
Diploma course 
Technikon degree 
University degree 
Other course: Specify________________________________ 
 
Missing 
1 
2 
3 
4 
5 
6 
7 
 
 
-66 
 
 
103 What is your source of income, if any? 
 
 
READ RESPONSES ONE BY ONE 
 
CIRCLE MORE THAN ONE IF NEEDED 
 
 
 
 
Are you paid a salary 
Are you self employed 
Do you receive a grant 
Do you receive financial support from  other members  of the  family 
Other  
Other: Specify_____________________________________ 
 
No Income  
 
Missing 
 
Yes      No  
1         0 
1         0 
1         0 
 
1         0 
1         0 
         
9   
 
-66 
 
 
 
 
 
SECTION-2: Use of Health Care Facilities  
READ: Now I would like to ask you some questions about your use of health care facilities. 
No. Questions and filters Coding categories Code Instructions 
201 When did you last visit any health care 
centre?  
 
 
 
CIRCLE ONLY ONE 
In the last month 
In the last 6 months 
In the last year 
In the last 5 years 
Unsure 
 
More than 5 years ago 
Missing 
 
1 
2 
3 
4 
88 
 
5 
-66 
 
 
      
 Skip to 203 
 
 
 
Skip to 202 
 
202 Why have you not visited a health care 
centre for more than 5 years 
 
 
DO NOT READ RESPONSES 
 
CIRCLE    IF MENTIONED 
 
Probes:  
 
Anything else? 
              
 
 
No health problem 
Don’t have the money 
Too far away 
No transport to get there 
Don’t have enough time to go there  
Don’t believe they can help my me with my health problem   
Have to wait too long at the clinic 
The service at the clinic is poor 
The clinic is not open when I can go there 
Other 
  Other: Specify__ _________________________________ 
Missing 
 
M     NM 
1         0 
1         0 
1         0 
1         0 
1         0 
1         0 
1         0 
1         0 
1         0 
1         0 
 
-66 
 
 
 
 
 
 Skip to 301 
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No. Questions and filters Coding categories Code Instructions 
203 Which service do you most often visit when 
you go for  health care? 
 
READ ALL RESPONSES 
THEN  
CIRCLE ONLY ONE 
Government  clinics 
Government hospitals 
Private doctors/hospitals 
Traditional healers 
Other 
Other: Specify________________________________ 
   
Missing  
 
1 
2 
3 
4 
5 
 
 
-66 
 
204 a) What is the name of the health care 
centre you most often visit?  
 
b) Is it easy to get to this facility? 
 
 
 
 
c) How do you usually travel to this facility? 
 
 
CIRCLE ONLY ONE 
 
 
NAME_______________________________________ 
 
 
 
 
Missing  
 
Walk 
Taxi 
Public transport 
Car 
 
Missing 
 
 
 
Yes      No  
1         0 
 
-66 
 
1 
2 
3 
4 
 
-66 
 
 
205 
 
What  was the reason for your most recent 
visit to any health care centre? 
 
READ RESPONSES ONE BY ONE  
 
CIRCLE MORE THAN ONE IF NEEDED 
 
 
For treatment of a disease     
For medicines for yourself 
For family planning for yourself  
For a Pap Smear or gynaecological examination for yourself  
To accompany  someone else 
Other 
 
Other: Specify_______ ________________________ 
 
Missing 
 
Yes      No  
1         0 
1         0 
1         0 
1         0 
1         0 
1         0 
 
 
 
-66 
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SECTION-3: Knowledge of Pap Smears and cancer of the cervix  
READ: “Now I would like to talk to you about cervical cancer and how to prevent it.” 
No. Questions and filters Coding categories Code Instructions 
301 a) Can you explain what you understand about 
cervical cancer – that is cancer of the mouth of 
the womb? 
 
 
IF CLIENT SAYS SHE KNOWS NOTHING 
ABOUT CERVCAL CANCER, SKIP TO 
SECTION 4 
 
 
 
 
OPEN RESPONSE 
 
_________________________________________ 
 
_________________________________________ 
 
__________________________________________ 
 
_________________________________________ 
 
_________________________________________ 
 
 
 
 
 
 
 
 
 
 
 
 
 
302 What changes in your body would make you think 
that you had cervical cancer? 
 
 
DO NOT READ RESPONSES 
CIRCLE   FOR ALL RESPONSES 
MENTIONED 
Probe: Anything else? 
 
 
Pain  
Discharge from vagina 
Odour from vagina 
Ulcers/sores on private parts 
Unusual bleeding 
There are no signs 
Don’t know 
Other  
 
Other: Specify_______________________________ 
 
Missing 
 
M     NM 
1         0 
1         0 
1         0 
1         0 
1         0 
1         0 
1         0 
1         0 
 
 
 
-66 
 
 
303 Do you know how a woman can protect herself 
against developing cervical cancer? 
 
Yes 
No 
Unsure 
 
Missing  
1 
0 
88 
 
-66 
 
Skip to 304 
Skip to 305 
Skip to 304 
 
304 How can a woman protect herself against 
developing cervical cancer? 
 
 
DO NOT READ RESPONSES 
CIRCLE   FOR ALL RESPONSES 
MENTIONED 
Probe: Anything else? 
 
 
Regular pap smear 
Regular examination of womb 
Seeing a special doctor 
Regular visit to General Practitioner  
Not having sex 
Using condoms 
Vaccine/injection 
Other screening tests 
Other  
 
Other: Specify_______ ________________________ 
 
Missing 
M     NM 
1         0 
1         0 
1         0 
1         0 
1         0 
1         0 
1         0 
1         0 
 
 
 
 
-66 
 
 
305 Do you think cervical cancer can be cured with 
treatment? 
 
Yes 
No 
Unsure 
 
Missing 
1 
0 
88 
 
-66 
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SECTION-4: Cervix cancer screening History 
READ: “Now I would like to ask you about any cervix cancer screening tests you may have had” 
No. Questions and filters Coding categories Code Instructions 
401 Have you ever had a test for cervical cancer?  Yes 
No 
Unsure 
 
Missing 
 
1 
0 
88  
 
-66 
Skip to 402 
Skip to 403 
Skip to 501 
 
402 If  YES 
What test did you have? 
 
DO NOT READ RESPONSES 
CIRCLE   FOR ALL RESPONSES 
MENTIONED 
Probe: Anything else? 
 
 
 
 
Pap smear 
Vaginal Examination 
Tampon test 
Other 
 
Other: specify______________________________ 
 
Missing 
 
M     NM 
1         0 
1         0 
1         0 
1         0 
 
 
 
-66 
 
 
 
  Skip to 404 
 
403 If   NO  
Why have you  never had a test for cervical 
cancer? 
 
 
DO NOT READ RESPONSES 
CIRCLE   FOR ALL RESPONSES 
MENTIONED 
Probe: 
 
 Anything else? 
 
 
Scared 
Embarrassed 
My partner wouldn’t like it 
I don’t have the money 
I don’t like having these kinds of tests 
I have never heard about this before 
Didn’t know where to go 
Didn’t think it would help me 
Did not have a reason to go for one 
Other 
  
Other specify____________________________ 
 
__________________________________________ 
 
Missing 
 
M     NM 
1         0 
1         0 
1         0 
1         0 
1         0 
1         0 
1         0 
1         0 
1         0 
1         0 
 
 
 
 
 
-66 
 
 
 
        
 
 
     Skip to 501 
 
404 How many years ago was your last test for cervical  
cancer? 
 
CIRCLE ONLY ONE 
Less than 1 year ago 
1-5 years 
6-10 years 
> 10 years ago 
Don’t know 
 
Missing 
1 
2 
3 
4 
88 
 
-66 
 
 
405 What was the result of your last test? 
 
CIRCLE ONLY ONE 
Normal 
Abnormal 
Don’t know 
 
Missing 
 
1 
0 
88 
 
-66 
Skip to 501 
Skip to 406 
Skip to 501 
 
406 Did you have any treatment for this? 
 
CIRCLE ONLY ONE 
Yes 
No 
Unsure 
 
Missing 
 
1 
0 
88  
 
-66 
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SECTION-5: Vaccination Knowledge and attitudes 
READ: “Now I would like to ask  you about  your opinions about vaccination and cervical cancer” 
 
No. Questions and filters Coding categories Code Skip To 
501 Have you ever heard of a vaccine or injection  to 
prevent cervical cancer? 
 
Yes 
No 
Unsure 
 
Missing 
 
1 
0 
88  
 
-66 
 
Skip to 502 
Skip to 503 
Skip to 503 
 
 
 
502 IF YES: Who is the vaccine or  injection  for? 
 
 
 
DO NOT READ RESPONSES 
CIRCLE   FOR ALL RESPONSES 
MENTIONED 
Probe: Anybody specific? 
 
 
 
 
Women/girls only  
Men and women/girls 
Women/girls under a certain age 
Women/girls  who have not had sexual intercourse yet 
Don’t know enough about it  
Other 
Other: Specify_______________________________ 
 
___________________________________________ 
 
Missing 
M     NM 
1         0 
1         0 
1         0 
1         0 
1         0 
1         0 
 
 
 
 
-66 
 
 
 
 
503 Do you think a vaccine to prevent cervical cancer  
would be good to have?  
 
 
Yes 
No 
Unsure 
Missing 
 
1 
0 
88 
 
-66 
Skip to 505 
Skip to 504 
Skip to 504 
 
 
 
504 IF NO or unsure: 
Why do you think it would not/ might not 
 be good to have a vaccination to prevent cervical 
cancer? 
End interview.  Thank the client for her help and 
ask: “Do you have any questions?” 
OPEN RESPONSE 
_________________________________________ 
 
_________________________________________ 
 
__________________________________________ 
 
  
 
505 
 
SAY: There is such a vaccine:  
 
ASK: Would you advise primary school girls to 
have it?  
End interview.  Thank the client for her help and 
ask: “Do you have any questions?” 
Yes 
No 
Unsure 
 
Missing 
1 
0 
88  
 
-66 
 
 
 
 
Signature of Interviewer (post-interview) ______________________________________  
(Your signature verifies that you have reviewed the responses given by the interviewee, corrected any problems, and that ALL questions have a 
response marked.) 
 
INTERVIEWER: Is this survey complete?   
 1 = Complete 
 2 = Incomplete 
 
If not complete please give reasons:  
 
_____________________________________________________________________________________________ 
 
_____________________________________________________________________________________________ 
 
_____________________________________________________________________________________________ 
 
End of first Interview
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VACCS Project – Second Interview 
 
SECTION-6: Knowledge of Pap Smears and cancer of the cervix  
READ: “Now I would like to talk to you about cervical cancer and how to prevent it.” 
No. Questions and filters Coding categories Code Instructions 
601 a) Can you explain what you understand about 
cervical cancer – that is cancer of the mouth of 
the womb? 
 
 
IF CLIENT SAYS SHE KNOWS NOTHING 
ABOUT CERVCAL CANCER, SKIP TO 
SECTION 4 
 
 
 
 
OPEN RESPONSE 
 
_________________________________________ 
 
_________________________________________ 
 
__________________________________________ 
 
_________________________________________ 
 
_________________________________________ 
 
 
 
 
 
 
 
 
 
 
 
 
 
602 What changes in your body would make you think 
that you had cervical cancer? 
 
 
DO NOT READ RESPONSES 
CIRCLE   FOR ALL RESPONSES 
MENTIONED 
Probe: Anything else? 
 
 
Pain  
Discharge from vagina 
Odour from vagina 
Ulcers/sores on private parts 
Unusual bleeding 
There are no signs 
Don’t know 
Other  
 
Other: Specify_______________________________ 
 
Missing 
 
M     NM 
1         0 
1         0 
1         0 
1         0 
1         0 
1         0 
1         0 
1         0 
 
 
 
-66 
 
 
603 Do you know how a woman can protect herself 
against developing cervical cancer? 
 
Yes 
No 
Unsure 
 
Missing  
1 
0 
88 
 
-66 
 
Skip to 304 
Skip to 305 
Skip to 304 
 
604 How can a woman protect herself against 
developing cervical cancer? 
 
 
DO NOT READ RESPONSES 
CIRCLE   FOR ALL RESPONSES 
MENTIONED 
Probe: Anything else? 
 
 
Regular pap smear 
Regular examination of womb 
Seeing a special doctor 
Regular visit to General Practitioner  
Not having sex 
Using condoms 
Vaccine/injection 
Other screening tests 
Other  
 
Other: Specify_______ ________________________ 
 
Missing 
M     NM 
1         0 
1         0 
1         0 
1         0 
1         0 
1         0 
1         0 
1         0 
 
 
 
 
-66 
 
 
605 Do you think cervical cancer can be cured with 
treatment? 
 
Yes 
No 
Unsure 
 
Missing 
1 
0 
88 
 
-66 
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SECTION-7: Cervix cancer screening History 
READ: “Now I would like to ask you about any cervix cancer screening tests you may have had” 
No. Questions and filters Coding categories Code Instructions 
701 Have you ever had a test for cervical cancer?  Yes 
No 
Unsure 
 
Missing 
 
1 
0 
88  
 
-66 
Skip to 402 
Skip to 403 
Skip to 501 
 
702 If  YES 
What test did you have? 
 
DO NOT READ RESPONSES 
CIRCLE   FOR ALL RESPONSES 
MENTIONED 
Probe: Anything else? 
 
 
 
 
Pap smear 
Vaginal Examination 
Tampon test 
Other 
 
Other: specify______________________________ 
 
Missing 
 
M     NM 
1         0 
1         0 
1         0 
1         0 
 
 
 
-66 
 
 
 
  Skip to 404 
 
703 If   NO  
Why have you  never had a test for cervical 
cancer? 
 
 
DO NOT READ RESPONSES 
CIRCLE   FOR ALL RESPONSES 
MENTIONED 
Probe: 
 
 Anything else? 
 
 
Scared 
Embarrassed 
My partner wouldn’t like it 
I don’t have the money 
I don’t like having these kinds of tests 
I have never heard about this before 
Didn’t know where to go 
Didn’t think it would help me 
Did not have a reason to go for one 
Other 
  
Other specify____________________________ 
 
__________________________________________ 
 
Missing 
 
M     NM 
1         0 
1         0 
1         0 
1         0 
1         0 
1         0 
1         0 
1         0 
1         0 
1         0 
 
 
 
 
 
-66 
 
 
 
        
 
 
     Skip to 501 
 
704 How many years ago was your last test for cervical  
cancer? 
 
CIRCLE ONLY ONE 
Less than 1 year ago 
1-5 years 
6-10 years 
> 10 years ago 
Don’t know 
 
Missing 
1 
2 
3 
4 
88 
 
-66 
 
 
705 What was the result of your last test? 
 
CIRCLE ONLY ONE 
Normal 
Abnormal 
Don’t know 
 
Missing 
 
1 
0 
88 
 
-66 
Skip to 501 
Skip to 406 
Skip to 501 
 
706 Did you have any treatment for this? 
 
CIRCLE ONLY ONE 
Yes 
No 
Unsure 
 
Missing 
 
1 
0 
88  
 
-66 
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SECTION-8: Vaccination Knowledge and attitudes 
READ: “Now I would like to ask  you about  your opinions about vaccination and cervical cancer” 
 
No. Questions and filters Coding categories Code Skip To 
801 Have you ever heard of a vaccine or injection  to 
prevent cervical cancer? 
 
Yes 
No 
Unsure 
 
Missing 
 
1 
0 
88  
 
-66 
 
Skip to 502 
Skip to 503 
Skip to 503 
 
 
 
802 IF YES: Who is the vaccine or  injection  for? 
 
 
 
DO NOT READ RESPONSES 
CIRCLE   FOR ALL RESPONSES 
MENTIONED 
Probe: Anybody specific? 
 
 
 
 
Women/girls only  
Men and women/girls 
Women/girls under a certain age 
Women/girls  who have not had sexual intercourse yet 
Don’t know enough about it  
Other 
Other: Specify_______________________________ 
 
___________________________________________ 
 
Missing 
M     NM 
1         0 
1         0 
1         0 
1         0 
1         0 
1         0 
 
 
 
 
-66 
 
 
 
 
803 Do you think a vaccine to prevent cervical cancer  
would be good to have?  
 
 
Yes 
No 
Unsure 
Missing 
 
1 
0 
88 
 
-66 
Skip to 505 
Skip to 504 
Skip to 504 
 
 
 
804 IF NO or unsure: 
Why do you think it would not/ might not 
 be good to have a vaccination to prevent cervical 
cancer? 
End interview.  Thank the client for her help and 
ask: “Do you have any questions?” 
OPEN RESPONSE 
_________________________________________ 
 
_________________________________________ 
 
__________________________________________ 
 
  
 
805 
 
SAY: There is such a vaccine:  
 
ASK: Would you advise primary school girls to 
have it?  
End interview.  Thank the client for her help and 
ask: “Do you have any questions?” 
Yes 
No 
Unsure 
 
Missing 
1 
0 
88  
 
-66 
 
 
 
 
Signature of Interviewer (post-interview) ______________________________________  
(Your signature verifies that you have reviewed the responses given by the interviewee, corrected any problems, and that ALL questions have a 
response marked.) 
 
INTERVIEWER: Is this survey complete?   
 1 = Complete 
 2 = Incomplete 
 
If not complete please give reasons:  
 
_____________________________________________________________________________________________ 
 
_____________________________________________________________________________________________ 
 
_____________________________________________________________________________________________ 
 
